Illumina Among the First in the World to Receive Science-Based Net-Zero Lens Approval


The SBTi is a global body that enables companies to set ambitious emission reduction targets in line with the latest climate science. Its Net-Zero Standard is the world’s first science-based certification of corporate net-zero goals, in line with the Paris Agreement goal of keeping global warming to 1.5°C.

“Illumina proudly joins the SBTi as the world’s first genomics company with a verified, science-based net zero goal,” said John Frank, Illumina’s director of public affairs. “This approach will help us demonstrate that our long-term net zero climate goals are credible, ambitious and accountable.”

Illumina SBTi Approved Targets

  • Net zero target
    • Commitment to achieving net zero GHG emissions in Illumina’s direct operations (Scope 1 and 2) and our value chain (Scope 3) by 2050 from its 2019 baselines
  • Short-term targets Commitments based on 2019 baselines
    • Reduce absolute GHG emissions from direct operations by 46% by 2030
    • Reduce absolute GHG emissions from indirect operations, focusing on value chain elements associated with purchased materials, transportation, investments, business travel and employee travel, by 46% by 2030
    • Increase annual renewable electricity supply from 0.6% in 2019 to 100% by 2030
  • Long-term target commitments based on 2019 baselines
    • Reduce absolute GHG emissions from direct operations by 90% by 2050
    • Reduce absolute GHG emissions from indirect operations associated with purchased goods and services, capital equipment, upstream transportation and distribution, business travel, employee travel and capital investment by 90% here 2050

In October 2021the SBTi launched the first Net zero corporate standard. In January 2022, it opened this certification to all companies, and Illumina was among the first to request verification of its net zero goal. Today, Illumina is among the first group of companies in the world to receive validation of its scientific objectives.

“The SBTi Net-Zero enterprise standard creates alignment and drives action,” Frank said. “Much work remains to be done, but we have committed to the most ambitious level of climate action and urge others to do the same.”

“As a scientific organization, we are obligated to ensure that our reduction targets are aligned and verified with a scientific approach,” said Sharon Vidal, Head of Corporate Social Responsibility at Illumina. “The validation of our net zero goals by the SBTi is essential to embedding environmental stewardship into the fabric of our operations.”

Illumina’s net-zero progress and sustainability performance will be disclosed in the annual report Corporate Social Responsibility Report.

Illumina’s climate action plan includes a $20 million philanthropic commitment to support initiatives dedicated to sustainable innovation and environmental justice, and goals to reduce water consumption intensity and landfill waste in direct operations. Click here to learn more about Illumina’s approach to environmental sustainability.

Use of forward-looking statements
This press release may contain forward-looking statements that involve risks and uncertainties. Important factors affecting our business that could cause actual results to differ materially from those set forth in the forward-looking statements include our ability to achieve our net zero goals in a timely manner, if at all. Other risk factors relating to our business are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed at conferences. public telephone numbers, the date and time of which are released beforehand. We assume no obligation, and do not intend, to update these forward-looking statements, review or confirm analysts’ expectations, or provide interim reports or quarterly progress updates. In progress.

About Illumina
Illumina improves human health by unlocking the power of the genome. Our focus on innovation has enabled us to become a global leader in DNA sequencing and chip-based technologies, serving customers in the research, clinical and application markets. Our products are used for applications in life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visitwww.illumina.comand join us onTwitter,Facebook,LinkedIn,instagramandYoutube.

Investors:
Salli Schwartz
858.291.6421
[email protected]

Media:
Adi Raval
US: 202.629.8172
[email protected]

SOURCEIllumina, Inc.

Previous EU authorizes rail transport of sanctioned Russian goods
Next University completes first phase of equitable compensation review and renews commitment to ongoing appointments